Compare NODK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NODK | SGHT |
|---|---|---|
| Founded | 1946 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.6M | 309.6M |
| IPO Year | 2016 | 2021 |
| Metric | NODK | SGHT |
|---|---|---|
| Price | $15.99 | $5.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 32.0K | ★ 174.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $285,050,000.00 | $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $26.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.23 | $3.11 |
| 52 Week High | $16.49 | $9.24 |
| Indicator | NODK | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 64.84 |
| Support Level | $13.03 | $4.76 |
| Resistance Level | N/A | $6.59 |
| Average True Range (ATR) | 0.38 | 0.32 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 55.37 | 82.79 |
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.